{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T03:32:40Z","timestamp":1791689560051,"version":"4.3.4"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2014,11,18]],"date-time":"2014-11-18T00:00:00Z","timestamp":1416268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,5,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>\u2003<\/jats:title>\n                    <jats:p>Bisphosphonates are widely used off-label in the treatment of patients with osteogenesis imperfecta (OI) with the intention of reducing the risk of fracture. Although there is strong evidence that bisphosphonates increase bone mineral density in osteogenesis imperfecta, the effects on fracture occurrence have been inconsistent. The aim of this study was to gain a better insight into the effects of bisphosphonate therapy on fracture risk in patients with osteogenesis imperfecta by conducting a meta-analysis of randomized controlled trials in which fractures were a reported endpoint. We searched Medline, Embase, and the Cochrane Central Register of Controlled Trials in which the effects of bisphosphonates on fracture risk in osteogenesis imperfecta were compared with placebo and conducted a meta-analysis of these studies using standard methods. Heterogeneity was assessed using the I2 statistic. Six eligible studies were identified involving 424 subjects with 751 patient-years of follow-up. The proportion of patients who experienced a fracture was not significantly reduced by bisphosphonate therapy (Relative Risk [RR]\u2009=\u20090.83 [95% confidence interval 0.69\u20131.01], p\u2009=\u20090.06) with no heterogeneity between studies (I2\u2009=\u20090). The fracture rate was reduced by bisphosphonate treatment when all studies were considered (RR\u2009=\u20090.71 [0.52\u20130.96], p\u2009=\u20090.02), but with considerable heterogeneity (I2\u2009=\u200936%) explained by one study where a small number of patients in the placebo group experienced a large number of fractures. When this study was excluded, the effects of bisphosphonates on fracture rate was not significant (RR\u2009=\u20090.79 [0.61\u20131.02], p\u2009=\u20090.07, I2\u2009=\u20090%). We conclude that the effects of bisphosphonates on fracture prevention in osteogenesis imperfecta are inconclusive. Adequately powered trials with a fracture endpoint are needed to further investigate the risks and benefits of bisphosphonates in this condition. \u00a9 2014 American Society for Bone and Mineral Research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jbmr.2410","type":"journal-article","created":{"date-parts":[[2014,11,18]],"date-time":"2014-11-18T17:05:51Z","timestamp":1416330351000},"page":"929-933","source":"Crossref","is-referenced-by-count":120,"title":["Bisphosphonates for the Prevention of Fractures in Osteogenesis Imperfecta: Meta-Analysis of Placebo-Controlled Trials"],"prefix":"10.1093","volume":"30","author":[{"given":"Jannie D","family":"Hald","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Internal MedicineAarhus University HospitalAarhusDenmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Evangelou","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and BiostatisticsImperial College LondonLondonUK"},{"name":"Department of Hygiene and EpidemiologyUniversity of Ioannina Medical SchoolIoanninaGreece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bente L","family":"Langdahl","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Internal MedicineAarhus University HospitalAarhusDenmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart H","family":"Ralston","sequence":"additional","affiliation":[{"name":"Rheumatology and Bone Disease Research GroupCentre for Genomic and Experimental MedicineInstitute of Genetics and Molecular MedicineEdinburgh UniversityWestern General HospitalEdinburghUK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,11,18]]},"reference":[{"key":"2024020319064671200_jbmr2410-bib-0001","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00223-012-9588-3","article-title":"Recent advances in osteogenesis imperfecta","volume":"90","author":"Cundy","year":"2012","journal-title":"Calcif Tissue Int."},{"key":"2024020319064671200_jbmr2410-bib-0002","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(78)90763-8","article-title":"Classification of osteogenesis imperfecta [letter]","volume":"1","author":"Sillence","year":"1978","journal-title":"Lancet."},{"key":"2024020319064671200_jbmr2410-bib-0003","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ajhg.2009.09.001","article-title":"PPIB mutations cause severe osteogenesis imperfecta","volume":"85","author":"van Dijk","year":"2009","journal-title":"Am J Hum Genet."},{"key":"2024020319064671200_jbmr2410-bib-0004","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ajhg.2012.06.005","article-title":"A single recurrent mutation in the 5'-UTR of IFITM5 causes osteogenesis imperfecta type V","volume":"91","author":"Cho","year":"2012","journal-title":"Am J Hum Genet."},{"key":"2024020319064671200_jbmr2410-bib-0005","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1136\/jmedgenet-2012-101142","article-title":"Study of autosomal recessive osteogenesis imperfecta in Arabia reveals a novel locus defined by TMEM38B mutation","volume":"49","author":"Shaheen","year":"2012","journal-title":"J Med Genet."},{"key":"2024020319064671200_jbmr2410-bib-0006","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/ajmg.a.34025","article-title":"Mutations in FKBP10 cause both Bruck syndrome,isolated osteogenesis imperfecta in humans","volume":"155A","author":"Shaheen","year":"2011","journal-title":"Am J Med Genet A."},{"key":"2024020319064671200_jbmr2410-bib-0007","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/ng1968","article-title":"Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal\/severe osteogenesis imperfecta","volume":"39","author":"Cabral","year":"2007","journal-title":"Nat Genet."},{"key":"2024020319064671200_jbmr2410-bib-0008","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1056\/NEJMoa063804","article-title":"Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta","volume":"355","author":"Barnes","year":"2006","journal-title":"N Engl J Med."},{"key":"2024020319064671200_jbmr2410-bib-0009","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.cell.2006.08.039","article-title":"CRTAP is required for prolyl 3-hydroxylation and mutations cause recessive osteogenesis imperfecta","volume":"127","author":"Morello","year":"2006","journal-title":"Cell."},{"key":"2024020319064671200_jbmr2410-bib-0010","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ajhg.2013.02.009","article-title":"WNT1 mutations in families affected by moderately severe and progressive recessive osteogenesis imperfecta","volume":"92","author":"Pyott","year":"2013","journal-title":"Am J Hum Genet."},{"key":"2024020319064671200_jbmr2410-bib-0011","first-page":"CD005088","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","author":"Phillipi","year":"2008","journal-title":"Cochrane Database Syst Rev."},{"key":"2024020319064671200_jbmr2410-bib-0012","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(04)16101-1","article-title":"Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study","volume":"363","author":"Sakkers","year":"2004","journal-title":"Lancet."},{"key":"2024020319064671200_jbmr2410-bib-0013","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S0140-6736(13)61091-0","article-title":"Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Bishop","year":"2013","journal-title":"Lancet."},{"key":"2024020319064671200_jbmr2410-bib-0014","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1359\/jbmr.090712","article-title":"A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta","volume":"25","author":"Bishop","year":"2010","journal-title":"J Bone Miner Res."},{"key":"2024020319064671200_jbmr2410-bib-0015","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1210\/jc.2010-0636","article-title":"Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study","volume":"96","author":"Ward","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"key":"2024020319064671200_jbmr2410-bib-0016","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1359\/JBMR.051015","article-title":"Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial","volume":"21","author":"Chevrel","year":"2006","journal-title":"J Bone Miner Res."},{"key":"2024020319064671200_jbmr2410-bib-0017","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1359\/JBMR.050109","article-title":"Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement","volume":"20","author":"Letocha","year":"2005","journal-title":"J Bone Miner Res."},{"key":"2024020319064671200_jbmr2410-bib-0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials."},{"key":"2024020319064671200_jbmr2410-bib-0019","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1359\/JBMR.041232","article-title":"Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study","volume":"20","author":"Gatti","year":"2005","journal-title":"J Bone Miner Res."},{"key":"2024020319064671200_jbmr2410-bib-0020","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1359\/jbmr.090213","article-title":"Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study","volume":"24","author":"Rauch","year":"2009","journal-title":"J Bone Miner Res."},{"key":"2024020319064671200_jbmr2410-bib-0021","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1359\/jbmr.090712","article-title":"A randomised controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta","volume":"25","author":"Bishop","year":"2010","journal-title":"J Bone Miner Res."},{"key":"2024020319064671200_jbmr2410-bib-0022","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00198-011-1658-2","article-title":"Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists","volume":"23","author":"Bradbury","year":"2012","journal-title":"Osteoporos Int."},{"key":"2024020319064671200_jbmr2410-bib-0023","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"N Engl J Med."},{"key":"2024020319064671200_jbmr2410-bib-0024","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/S0140-6736(06)68891-0","article-title":"Osteoporosis","volume":"367","author":"Sambrook","year":"2006","journal-title":"Lancet."},{"key":"2024020319064671200_jbmr2410-bib-0025","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00223-010-9364-1","article-title":"Adverse effects of bisphosphonates","volume":"86","author":"Abrahamsen","year":"2010","journal-title":"Calcif Tissue Int."},{"key":"2024020319064671200_jbmr2410-bib-0026","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.5037\/jomr.2013.4401","article-title":"Systematic review on the incidence of bisphosphonate related osteonecrosis of the jaw in children diagnosed with osteogenesis imperfecta","volume":"4","author":"Hennedige","year":"2013","journal-title":"J Oral Maxillofac Res."},{"key":"2024020319064671200_jbmr2410-bib-0027","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11832-011-0380-0","article-title":"Changing pattern of femoral fractures in osteogenesis imperfecta with prolonged use of bisphosphonates","volume":"6","author":"Nicolaou","year":"2012","journal-title":"J Child Orthop."}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.2410","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jbmr.2410","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jbmr.2410","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/30\/5\/929\/56568150\/jbmr2410.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/30\/5\/929\/56568150\/jbmr2410.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T10:53:19Z","timestamp":1710327199000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/30\/5\/929-933\/7599239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,18]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,11,18]]},"published-print":{"date-parts":[[2015,5,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.2410","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725241380.793509194","asserted-by":"object"}]},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,5,1]]},"published":{"date-parts":[[2014,11,18]]}}}